biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
06:14 Menopause brings sudden body-wide changes, not a slow slide, study says✦11:51 Putting force on old mice's leg bones helped them live about 9% longer✦06:17 Stem cell implants helped 9 Parkinson's patients move better, maker says✦05:42 Siblings born deaf respond to sounds after a newly approved gene therapy✦06:20 US gives up to $41M to test existing drugs for preventing Alzheimer's✦06:18 80-year-old's blood cells become brain stem cells that test under age 20✦05:46 Pill meant to help older dogs live longer is one FDA step from approval✦11:54 Cold helps worms live longer via a chemical their muscles send out✦06:14 Menopause brings sudden body-wide changes, not a slow slide, study says✦11:51 Putting force on old mice's leg bones helped them live about 9% longer✦06:17 Stem cell implants helped 9 Parkinson's patients move better, maker says✦05:42 Siblings born deaf respond to sounds after a newly approved gene therapy✦06:20 US gives up to $41M to test existing drugs for preventing Alzheimer's✦06:18 80-year-old's blood cells become brain stem cells that test under age 20✦05:46 Pill meant to help older dogs live longer is one FDA step from approval✦11:54 Cold helps worms live longer via a chemical their muscles send out
← People to follow
Jacob Kimmel
Photo: Matthew Lampe, Public domain, via Wikimedia Commons
PERSON TO FOLLOW

Jacob Kimmel

Co-founder and CEO, NewLimit

Computational biologist who co-founded NewLimit in 2021 with Brian Armstrong and Blake Byers. He previously worked at Calico, the Alphabet-backed aging company, and leads NewLimit's scientific strategy.

epigenetic reprogrammingcomputational biologyliver diseaselongevity biotech

WHAT TO WATCHWhether NewLimit files for and starts its first human trial in alcohol-related liver disease in 2027.

ON THE WIRE

Every story about Jacob’s work.

Profile sources

  1. 1
    Endpoints 11: NewLimit searches far beyond Yamanaka for a new class of anti-aging medicines Endpoints News
  2. 2
    NewLimit — $3.1B · CEO Jacob Kimmel Silicon Valley Investclub
  3. 3
    NewLimit: Using Epigenetic Reprogramming to Reverse Cellular Excedr